SCHEMBL7933261

SCHEMBL7933261

Nc1ncccc1NCc1cccc(NC(=O)c2ccc3ccccc3n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.62
SMN1; SMN2 Q16637 4/20 0.51
NFKB1 P19838 3/20 0.51
RAB9A P51151 3/20 0.51
NFKB2 Q00653 3/20 0.51
RELA Q04206 3/20 0.51
MAPT P10636 6/20 0.50
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPK1 P28482 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
LMNA P02545 3/20 0.48
HCRTR1 O43613 1/20 0.48
NPC1 O15118 2/20 0.47
KDM4E B2RXH2 1/20 0.47
TP53 P04637 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.46
ACKR3 P25106 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7939649 0.88 BACE1 (0.68) BACE1SMN1; SMN2RAB9AMAPTALDH1A1
SCHEMBL7942249 0.86 RAB9A (0.48) BACE1SMN1; SMN2NFKB1RAB9ANFKB2
SCHEMBL7942432 0.85 BACE1 (0.69) BACE1HDAC4MEF2DEP300
SCHEMBL7933283 0.84 ALDH1A1 (0.50) BACE1SMN1; SMN2NFKB1RAB9ANFKB2
SCHEMBL7933183 0.83 BACE1 (0.71) BACE1
SCHEMBL7944661 0.83 BACE1 (0.71) BACE1KDM4EACKR3
SCHEMBL7940965 0.82 BACE1 (0.70) BACE1ACKR3
SCHEMBL7933424 0.82 BACE1 (0.73) BACE1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL7944667 0.82 BACE1 (0.70) BACE1
SCHEMBL7941663 0.81 BACE1 (0.58) BACE1SMN1; SMN2NFKB1RAB9ANFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885SMN1; SMN2 576/4885NFKB1 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.